vs

Side-by-side financial comparison of LESAKA TECHNOLOGIES INC (LSAK) and Zimmer Biomet (ZBH). Click either name above to swap in a different company.

LESAKA TECHNOLOGIES INC is the larger business by last-quarter revenue ($3.0B vs $2.1B, roughly 1.4× Zimmer Biomet). Zimmer Biomet runs the higher net margin — 11.4% vs 0.0%, a 11.4% gap on every dollar of revenue. On growth, Zimmer Biomet posted the faster year-over-year revenue change (9.3% vs 0.2%). Over the past eight quarters, LESAKA TECHNOLOGIES INC's revenue compounded faster (352.8% CAGR vs 3.7%).

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

Zimmer Biomet Holdings, Inc. is a publicly traded American medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

LSAK vs ZBH — Head-to-Head

Bigger by revenue
LSAK
LSAK
1.4× larger
LSAK
$3.0B
$2.1B
ZBH
Growing faster (revenue YoY)
ZBH
ZBH
+9.1% gap
ZBH
9.3%
0.2%
LSAK
Higher net margin
ZBH
ZBH
11.4% more per $
ZBH
11.4%
0.0%
LSAK
Faster 2-yr revenue CAGR
LSAK
LSAK
Annualised
LSAK
352.8%
3.7%
ZBH

Income Statement — Q1 FY2027 vs Q1 FY2026

Metric
LSAK
LSAK
ZBH
ZBH
Revenue
$3.0B
$2.1B
Net Profit
$437.0K
$238.3M
Gross Margin
64.6%
Operating Margin
2.2%
17.9%
Net Margin
0.0%
11.4%
Revenue YoY
0.2%
9.3%
Net Profit YoY
30.5%
EPS (diluted)
$1.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LSAK
LSAK
ZBH
ZBH
Q3 26
$3.0B
Q1 26
$2.1B
Q4 25
$178.7M
$2.2B
Q3 25
$171.4M
$2.0B
Q2 25
$168.5M
$2.1B
Q1 25
$161.4M
$1.9B
Q4 24
$176.2M
$2.0B
Q3 24
$153.6M
$1.8B
Net Profit
LSAK
LSAK
ZBH
ZBH
Q3 26
$437.0K
Q1 26
$238.3M
Q4 25
$3.6M
$139.4M
Q3 25
$-4.3M
$230.9M
Q2 25
$-28.4M
$152.8M
Q1 25
$-22.1M
$182.0M
Q4 24
$-32.5M
$239.5M
Q3 24
$-4.5M
$249.1M
Gross Margin
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
64.6%
Q4 25
31.4%
64.7%
Q3 25
30.9%
72.1%
Q2 25
28.9%
71.5%
Q1 25
27.5%
71.2%
Q4 24
25.7%
71.0%
Q3 24
22.6%
70.5%
Operating Margin
LSAK
LSAK
ZBH
ZBH
Q3 26
2.2%
Q1 26
17.9%
Q4 25
1.2%
6.9%
Q3 25
0.2%
17.6%
Q2 25
-16.7%
14.4%
Q1 25
0.4%
15.3%
Q4 24
0.3%
19.2%
Q3 24
-0.0%
15.3%
Net Margin
LSAK
LSAK
ZBH
ZBH
Q3 26
0.0%
Q1 26
11.4%
Q4 25
2.0%
6.2%
Q3 25
-2.5%
11.5%
Q2 25
-16.9%
7.4%
Q1 25
-13.7%
9.5%
Q4 24
-18.4%
11.8%
Q3 24
-3.0%
13.7%
EPS (diluted)
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
$1.22
Q4 25
$0.04
$0.71
Q3 25
$-0.05
$1.16
Q2 25
$-0.40
$0.77
Q1 25
$-0.27
$0.91
Q4 24
$-0.40
$1.18
Q3 24
$-0.07
$1.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LSAK
LSAK
ZBH
ZBH
Cash + ST InvestmentsLiquidity on hand
$1.5B
$424.2M
Total DebtLower is stronger
$3.2B
$7.5B
Stockholders' EquityBook value
$12.7B
Total Assets
$11.5B
$22.7B
Debt / EquityLower = less leverage
0.59×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LSAK
LSAK
ZBH
ZBH
Q3 26
$1.5B
Q1 26
$424.2M
Q4 25
$69.5M
$591.9M
Q3 25
$72.2M
$1.3B
Q2 25
$76.5M
$556.9M
Q1 25
$71.0M
$1.4B
Q4 24
$60.6M
$525.5M
Q3 24
$49.7M
$569.0M
Total Debt
LSAK
LSAK
ZBH
ZBH
Q3 26
$3.2B
Q1 26
$7.5B
Q4 25
$216.8M
Q3 25
$208.1M
Q2 25
$200.8M
Q1 25
$194.7M
Q4 24
$148.7M
Q3 24
$148.5M
Stockholders' Equity
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
$12.7B
Q4 25
$180.6M
$12.7B
Q3 25
$170.4M
$12.8B
Q2 25
$161.6M
$12.5B
Q1 25
$185.2M
$12.4B
Q4 24
$193.3M
$12.5B
Q3 24
$184.2M
$12.4B
Total Assets
LSAK
LSAK
ZBH
ZBH
Q3 26
$11.5B
Q1 26
$22.7B
Q4 25
$704.6M
$23.1B
Q3 25
$652.9M
$23.5B
Q2 25
$653.7M
$22.9B
Q1 25
$649.2M
$22.2B
Q4 24
$640.6M
$21.4B
Q3 24
$551.9M
$21.7B
Debt / Equity
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
0.59×
Q4 25
1.20×
Q3 25
1.22×
Q2 25
1.24×
Q1 25
1.05×
Q4 24
0.77×
Q3 24
0.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LSAK
LSAK
ZBH
ZBH
Operating Cash FlowLast quarter
$359.4M
Free Cash FlowOCF − Capex
$245.9M
FCF MarginFCF / Revenue
11.8%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.51×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
$359.4M
Q4 25
$-10.9M
$517.4M
Q3 25
$8.9M
$418.7M
Q2 25
$-9.1M
$378.2M
Q1 25
$10.7M
$382.8M
Q4 24
$-9.2M
$506.3M
Q3 24
$-4.1M
$395.7M
Free Cash Flow
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
$245.9M
Q4 25
$-14.8M
$442.6M
Q3 25
$4.9M
$363.7M
Q2 25
$-13.2M
$328.1M
Q1 25
$7.8M
$338.2M
Q4 24
$-15.5M
$454.8M
Q3 24
$-8.1M
$351.2M
FCF Margin
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
11.8%
Q4 25
-8.3%
19.7%
Q3 25
2.9%
18.2%
Q2 25
-7.8%
15.8%
Q1 25
4.9%
17.7%
Q4 24
-8.8%
22.5%
Q3 24
-5.3%
19.3%
Capex Intensity
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
Q4 25
2.2%
3.3%
Q3 25
2.3%
2.7%
Q2 25
2.4%
2.4%
Q1 25
1.7%
2.3%
Q4 24
3.6%
2.5%
Q3 24
2.6%
2.4%
Cash Conversion
LSAK
LSAK
ZBH
ZBH
Q3 26
Q1 26
1.51×
Q4 25
-2.99×
3.71×
Q3 25
1.81×
Q2 25
2.48×
Q1 25
2.10×
Q4 24
2.11×
Q3 24
1.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons